Zhenya Lindgardt Sells 21,158 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Key Points

• Sera Prognostics CEO Zhenya Lindgardt sold 21,158 shares of stock for a total of $66,647.70, reducing their ownership by 2.54% to 811,136 shares.
• Following the CEO's sale, Sera Prognostics' stock price dropped by 2.2% to $3.10, and the company has a market capitalization of $116.78 million.
• Wall Street analysts have downgraded Sera Prognostics from a "hold" rating to a "sell" rating, reflecting concerns over the company's financial performance.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 21,158 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total transaction of $66,647.70. Following the transaction, the chief executive officer owned 811,136 shares in the company, valued at $2,555,078.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Zhenya Lindgardt also recently made the following trade(s):

• On Thursday, September 11th, Zhenya Lindgardt sold 3,246 shares of Sera Prognostics stock. The shares were sold at an average price of $3.13, for a total transaction of $10,159.98.

Sera Prognostics Price Performance

Sera Prognostics stock traded up $0.03 during mid-day trading on Friday, reaching $3.10. 44,671 shares of the company traded hands, compared to its average volume of 105,485. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $9.13. The company has a market capitalization of $116.78 million, a price-to-earnings ratio of -3.65 and a beta of 1.00. The firm's fifty day moving average is $2.81 and its two-hundred day moving average is $2.85.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.05. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Sera Prognostics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th.

Institutional Trading of Sera Prognostics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its position in Sera Prognostics by 1.2% during the first quarter. Baker BROS. Advisors LP now owns 5,498,170 shares of the company's stock valued at $20,233,000 after buying an additional 63,771 shares during the period. Aberdeen Group plc grew its position in Sera Prognostics by 79.6% during the second quarter. Aberdeen Group plc now owns 2,227,367 shares of the company's stock valued at $6,170,000 after buying an additional 987,367 shares during the period. AWM Investment Company Inc. grew its position in Sera Prognostics by 48.1% during the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company's stock valued at $3,190,000 after buying an additional 281,703 shares during the period. Captrust Financial Advisors grew its position in Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company's stock valued at $1,668,000 after buying an additional 100,366 shares during the period. Finally, Northern Trust Corp grew its position in Sera Prognostics by 11.8% during the fourth quarter. Northern Trust Corp now owns 272,860 shares of the company's stock valued at $2,221,000 after buying an additional 28,863 shares during the period. Institutional investors and hedge funds own 54.64% of the company's stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.